Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Meta Expands AI Training With Employee Activity Tracking Tools 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DURHAM, N.C., March 01, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 36th Annual Cowen and Company Health Care Conference on Tuesday, March 8, 2016 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals to address unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir, a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
